Mitochondrial complex 1 Inhibitors
1 drugsAbout Mitochondrial complex 1
Mitochondrial complex I, or NADH:ubiquinone oxidoreductase, is a key enzyme in the mitochondrial electron transport chain, initiating cellular respiration and ATP production. As the largest complex, it plays a vital role in cellular energy generation. Disruptions can have far-reaching consequences.
Mitochondrial complex I is a compelling target for drug development, particularly where cellular energy production is compromised. Currently, there is no genetic evidence data available linking mitochondrial complex I to specific diseases.
There is one FDA-approved drug, FLYRCADO (GE HLTHCARE), targeting mitochondrial complex I for cardiovascular conditions. The drug is a small molecule. GE HLTHCARE is the only company with an approved drug.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Cesarean Section Complications with only 1 trials.
Top Mitochondrial complex 1 Drugs
GE HLTHCARE is the only company with an approved drug targeting mitochondrial complex I.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in the target's validation.
Mitochondrial complex 1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Mitochondrial complex 1, using small molecule modality.
Explore opportunities for alternative modalities like antibodies or peptides to differentiate from existing therapies.
Mitochondrial complex 1 Clinical Trials 1 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Mitochondrial complex 1 Drug Approval Timeline (2024 - 2024)
The first and most recent drug, FLYRCADO, was approved in 2024.
Recent approval suggests renewed interest, but limited history indicates uncertainty in long-term success.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: Moderate (8 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 8 clinical trials targeting Mitochondrial complex 1.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities